Ligand Pharmaceuticals Incorporated revised earning guidance for the full year of 2017. For the year, the company anticipates revenue to be approximately $140 million with adjusted earnings of $3.13 to $3.16 per share, as compared to prior guidance of $134 million to $136 million in revenue and adjusted profit of between $2.95 to $3 per share. The increase in guidance is because of milestone payments and royalties on the successful development of antibodies and to share sub-license revenue on out-licensed antibodies.